STOCK TITAN

Turn Therapeutics (TTRX) S-3 Filings

TTRX NASDAQ

Here are the S-3 shelf registrations from Turn Therapeutics Inc. (TTRX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

An S-3 covers the shelf registration that lets an established company sell over time, so if you follow TTRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TTRX filings page.

Rhea-AI Summary

Turn Therapeutics Inc. may offer and sell, from time to time after the registration statement becomes effective, securities with an aggregate initial offering price of up to $150,000,000 under a shelf prospectus; each offering’s terms will be set in a prospectus supplement. Up to $50,000,000 of common stock under its sales agreement with TD Cowen is included in, not additional to, the shelf amount. Net proceeds are intended for general corporate purposes, including research and development, preclinical and clinical development, acquisitions or in-licensing, debt repayment, working capital and capital expenditures, unless a supplement specifies otherwise.

The company’s lead candidate, GX-03, is in a staged Phase 2 trial for atopic dermatitis. Phase 2a had 50 subjects complete the study; Phase 2b is planned to enroll 120-136 patients, with topline results expected in the first quarter of 2027. Turn plans to initiate a Phase 2a study of GX-03 for hidradenitis suppurativa in the first quarter of 2027. Common shares outstanding totaled 30,572,704 as of November 6, 2026, and the stock closed at $9.48 per share that day.

Rhea-AI Summary

Turn Therapeutics Inc. (TTRX) registers for resale up to 25,362,950 shares of common stock by selling stockholders, including up to 6,621,190 shares by GEM. Of the total, 873,000 shares are being registered for the first time; other shares were originally registered under prior registration statements. The resale amount equals approximately 82.96% of the 30,572,704 common shares outstanding as of November 6, 2026.

The company will receive no proceeds from stockholder resales. Separately, it may sell shares to GEM under the GEM Purchase Agreement for up to $85.0 million in aggregate gross proceeds after the prospectus date, using draw-down notices; intended uses are working capital and general corporate purposes. GEM's purchase price is 90% of the average daily closing price during the applicable 15 consecutive trading days, with a $1.00-per-share floor. A requested draw-down cannot exceed 300% of average daily trading volume during the preceding 15 trading days. The prospectus estimates up to $84.95 million in net proceeds over approximately 36 months, assuming $85.0 million in aggregate gross proceeds. Of GEM's shares, 5,023,231 issuable under draw-down notices are registered for resale here; additional shares sold to GEM would first require an effective registration statement or amendment.